Patient Outcomes

FDA Grants Fast Track to Palvella’s QTORIN Rapamycin for Angiokeratomas

The move positions Palvella for faster FDA engagement on a 2026 Phase 2 study targeting a bleeding skin disorder with no approved therapies.